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INTRODUCTION
People	 living	 with	 HIV	 (PLHIV)	 require	 antiretroviral	
therapy	 (ART)	 as	 part	 of	 comprehensive	 HIV	 care	 ser-










pre-	treatment	 loss	 to	 follow-	up	 and	 was	 recommended	
by	WHO	in	their	2017	Guidelines for Managing Advanced 











immune	 reconstitution	 inflammatory	 syndrome	 (IRIS)	
occurring	in	people	with	undiagnosed	and	untreated	TB	
at	the	time	of	ART	initiation	[7].	However,	TB	symptoms	











sputum.	 If	 all	 people	 with	TB	 symptoms	 requiring	 ART	
initiation	had	ART	initiation	deferred,	then	a	large	num-




We	 undertook	 a	 systematic	 review	 to	 synthesize	 the	
evidence	on	the	risks	and	benefits	of	same-	day	ART	initia-
tion	in	PLHIV,	not	already	on	ART	and	with	TB	symptoms.	
Because	 there	 were	 very	 few	 studies	 that	 addressed	 this	
question	 directly	 by	 describing	 their	 TB	 screening	 algo-
rithm,	we	additionally	undertook	a	narrative	review	of	all	
identified	studies	of	same-	day	ART	initiation,	regardless	
of	 whether	 or	 how	TB	 screening	 was	 reported,	 in	 order	
to	make	recommendations	for	further	research	priorities.
METHODS






ing	 this	 direct	 comparison	 was	 identified.	 Therefore	 we	
included	 studies	 that	 recruited	 a	 group	 of	 PLHIV	 at	 the	
point	of	first	presentation	for	ART	and	where	there	was	an	
intention	to	start	at	least	some	people	on	same-	day	ART	
(i.e.	 those	 who	 were	 ‘eligible’	 for	 same-	day	 ART	 would	
not	start	same-	day	ART).	Two	studies	permitted	some	people	with	tuberculosis	
symptoms	to	start	same-	day	ART,	and	fewer	people	deferred	ART	(2%	and	16%	








K E Y W O R D S
guidelines,	HIV,	same-	day	ART,	tuberculosis,	tuberculosis	screening
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start)	and	where	TB	screening	procedures	and	how	these	
affected	eligibility	for	same-	day	ART	were	described.	The	
TB	 screen	 could	 take	 any	 form	 (i.e.	 symptoms	 or	 symp-
toms	and	same-	day	tests).
We	included	studies	that	reported	one	or	more	of	the	
following	 outcomes	 of	 interest:	 time	 to	 ART	 initiation;	
ART	 retention;	 viral	 load	 suppression;	 serious	 adverse	
events;	IRIS	events;	or	mortality.	Studies	could	be	in	any	
country	and	among	adults	or	children.	We	excluded	stud-
ies	 where	 participants	 were	 ‘pre-	screened’	 for	TB	 before	
enrolling	in	study,	or	where	outcomes	were	only	reported	






ison	group	and	 single	arms	of	multi-	arm	 trials	 could	be	
included.	As	a	secondary	objective,	because	so	few	studies	




On	 12	 March	 2020	 we	 searched	 the	 following	 databases	
using	terms	around	ART	and	same-	day	or	rapid	initiation:	
Ebsco	 Africa-	Wide	 Information;	 Ebsco	 CINAHL	 Plus;	
Wiley	 Cochrane	 Central	 Register	 of	 Controlled	 Trials;	
OvidSP	 Embase;	 OvidSP	 Global	 Health;	 World	 Health	
Organization	 Global	 Index	 Medicus;	 OvidSP	 Medline;	
and	 Clarivate	 Analytics	 Web	 of	 Science.	 We	 included	




International	 Clinical	 Trials	 Registry	 Platform	 on	 12	
March	2020.	The	search	strategy	is	available	at	PROSPERO	
(CRD42020205490,








reference	 lists	 from	selected	manuscripts	 to	 identify	any	
additional	relevant	studies.
Data extraction and synthesis
Data	of	study	characteristics	(country,	population,	details	
of	 TB	 screening,	 other	 eligibility	 criteria	 for	 same-	day	
F I G U R E  1  Schema	of	how	an	intervention	to	screen	for	tuberculosis	(TB)	to	determine	same-	day	antiretroviral	therapy	(ART)	eligibility	
might	lead	to	participant	harms	or	benefits.	IRIS,	immune	reconstitution	inflammatory	syndrome;	LTFU,	loss	to	follow-	up.	Ticks	represent	
possible	benefits	and	crosses	possible	harms
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ART)	and	outcomes	(as	described	above)	were	extracted	
by	 RMB	 and	 HR	 from	 included	 studies	 into	 a	 spread-
sheet	 in	 duplicate	 and	 discrepancies	 were	 reconciled	 by	
consensus.	 We	 contacted	 authors	 of	 papers	 where	 we	
thought	there	might	be	relevant	information	not	included	
in	the	published	paper.	We	synthesized	data	in	narrative	










two	 or	 more	 approaches	 to	 determining	 eligibility	 for	
same-	day	ART	based	on	TB	screening.	We	identified	four	
eligible	studies	where	a	TB	screening	algorithm	was	used	








count	 <350  cells/μL	 were	 permitted	 to	 start	 same-	day	
ART	 if	 they	 had	 none	 of	 the	 four	 WHO	 TB	 symptoms.	
People	with	TB	symptoms	were	asked	to	submit	sputum	
for	Xpert	and	could	start	ART	if	Xpert-	negative	(in	effect,	
meaning	 not	 on	 the	 same	 day	 as	 first	 presentation	 for	
most	people),	or	two	weeks	after	TB	treatment	initiation	
if	 Xpert	 positive.	 CASCADE	 was	 a	 trial	 of	 home-	based	
HIV	testing	and	same-	day	ART	initiation	in	Lesotho	[10].	
People	newly	diagnosed	with	HIV	could	start	ART	on	the	
same	 day	 as	 their	 HIV	 test	 regardless	 of	 TB	 symptoms.	
Participants	were	asked	about	TB	symptoms	and	anyone	
with	one	or	more	of	four	WHO	TB	symptoms	was	asked	
to	 provide	 sputum	 for	 Xpert	 testing,	 but	 was	 permitted	
to	start	ART	without	waiting	 for	 the	result.	 In	SLATE	I,	
F I G U R E  2  Preferred	Reporting	Items	for	Systematic	Reviews	and	Meta-	Analyses	diagram
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T A B L E  1 	 Characteristics	of	included	studies
Study
Parameter
Rosen et al. [9]
(RAPiT)
Labhardt et al. [10]
(CASCADE)
Rosen et al. [11]
(SLATE I)
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Study
Parameter
Rosen et al. [9]
(RAPiT)
Labhardt et al. [10]
(CASCADE)
Rosen et al. [11]
(SLATE I)















































































































T A B L E  1 	 (Continued)
(Continues)
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participants	 at	 primary	 care	 clinics	 in	 South	 Africa	 and	
Kenya	 were	 eligible	 to	 start	 same-	day	 ART	 only	 if	 they	





as	 SLATE	 I),	 could	 start	 ART	 if	 they	 had	TB	 symptoms	
Study
Parameter
Rosen et al. [9]
(RAPiT)
Labhardt et al. [10]
(CASCADE)
Rosen et al. [11]
(SLATE I)














































































T A B L E  1 	 (Continued)
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In	RapIT,	29/187	 (16%)	people	assessed	 for	 same-	day	
ART	 eligibility	 reported	 TB	 symptoms	 and	 4/187	 (2%)	










ipants	 who	 newly	 tested	 HIV-	positive,	 were	 not	 already	
on	 ART	 and	 were	 assigned	 to	 the	 same-	day	 ART	 arm	
reported	 TB	 symptoms,	 but	 no-	one	 was	 diagnosed	 with	
TB,	either	at	enrolment	or	during	follow-	up.	At	one	year,	
in	the	same-	day	arm,	69/137	(50%)	were	retained	in	care	
with	 a	 documented	 undetectable	 viral	 load,	 4/137	 (3%)	
had	 an	 unsuppressed	 viral	 load,	 15/137	 (11%)	 were	 in	
care	without	viral	 load	measurement	and	the	remaining	
49/137	(36%)	never	linked	to	clinic	ART	care.
In	 SLATE	 I,	 202/538	 (47%)	 people	 being	 assessed	 for	
same-	day	 ART	 reported	 TB	 symptoms	 and	 21/538	 (4%)	









symptoms,	 but	 were	 nonetheless	 started	 on	 ART	 on	 the	
same	day	by	the	government	usual	care	staff.
In	 SLATE	 II,	 140/296	 (47%)	 participants	 had	 one	 or	
more	WHO	TB	symptom.	However,	as	participants	with	
TB	 symptoms	 remained	 eligible	 for	 same-	day	 ART	 in	
SLATE	II,	only	41/296	(14%)	participants	were	ineligible	
for	 same-	day	 ART.	 Seven	 people	 (2%)	 were	 diagnosed	
with	TB	as	a	result	of	investigations	initiated	at	baseline;	
two	of	these	had	been	assessed	as	eligible	and	started	on	
same-	day	 ART,	 a	 third	 person	 was	 assessed	 as	 ineligi-
ble	by	SLATE	II	algorithm	but	was	 started	on	same-	day	
















initiation	 to	 await	 results	 of	TB	 tests	 [21-	23].	 One	 study	
reported	results	 from	an	HIV	testing	and	same-	day	ART	
programme	 for	 key	 populations	 in	 Nigeria.	 Out	 of	 709	
who	 started	 same-	day	 ART,	 nine	 (1.2%)	 had	 TB	 signs	
(these	were	not	defined	 in	the	paper).	The	TB	screening	
procedure	was	not	detailed	and	211	people	were	reported	
to	 have	 positive	 HIV	 tests	 in	 a	 community	 testing	 cam-
paign	but	did	not	start	ART	for	unstated	reasons	[15].	Two	
studies	mentioned	TB	screening	 in	 the	context	of	 same-	
day	ART	among	pregnant	women,	both	in	South	Africa.	





to	 TB	 [32].	 In	 the	 other	 study	 16/134	 pregnant	 women	
who	were	assessed	were	ineligible	for	same-	day	ART	start	
and	in	5/16	this	was	due	to	a	requirement	for	a	medical	
























determine	 eligibility	 for	 same-	day	 ART	 initiation.	 There	
were	no	trials	that	directly	compared	two	different	meth-
ods	of	TB	screening	to	determine	eligibility	for	same-	day	
ART.	 We	 identified	 four	 studies,	 all	 of	 which	 were	 ran-
domized	trials	of	same-	day	ART	initiation	(for	those	eli-
gible)	versus	standard	ART	initiation,	and	included	data	




ART.	 In	 two	 studies,	 a	 policy	 of	 allowing	 some	 people	
































after	 comparison	 shows	 that	 using	 the	 more	 permissive	
SLATE	II	algorithm	allowed	more	people	to	initiate	same-	
day	ART	(87%	vs.	61%)	and	to	initiate	ART	within	28 days	





was	 uncommon,	 ranging	 between	 0%	 to	 4%.	 No	 adverse	
events	related	to	TB	and	no	episodes	of	TB-	IRIS	were	re-
ported	in	either	CASCADE	or	SLATE	II.
In	 21/27	 of	 the	 other	 observational	 studies	 we	 re-
viewed,	 there	 was	 no	 mention	 at	 all	 of	 TB	 screening	
prior	to	same-	day	ART	initiation.	It	was	unclear	whether	
this	was	because	TB	screening	was	done	but	the	results	
were	 not	 reported,	 or	 because	 TB	 screening	 was	 not	
performed.
There	 are	 some	 limitations	 to	 our	 review.	 We	 only	




with	 authors	 of	 all	 included	 trials	 for	 additional	 details,	
but	did	not	speak	to	authors	of	all	observational	studies	or	





for	 most	 PLHIV.	 ‘Treat	 all’	 (i.e.	 ART	 initiation	 at	 any	
CD4	 count)	 was	 recommended	 by	 WHO	 in	 2015,	 and,	
in	 2017,	 same-	day	 ART	 start	 was	 recommended	 [3,43].	
Same-	day	ART	has	been	shown	to	reduce	pre-	treatment	









While	 there	are	 still	 some	questions	about	how	early	
ART	should	be	started	in	people	with	diagnosed	TB,	the	
group	 of	 people	 with	 TB	 symptoms	 but	 without	 firmly	
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Anecdotally,	 some	 ART	 providers	 are	 already	 mov-






















starting	 ART	 even	 though	 everyone	 had	 negative	 TB	
tests	(urine	LAM,	chest	X-	ray	and	sputum	Xpert)	prior	









a	 single	 day	 prior	 to	 ART	 initiation,	 and	 which	 can	
clearly	 divide	 people	 into	 one	 group	 who	 do	 not	 need	





a	period	of	days	or	 short	weeks	as	 test	 results	become	
available	 and	 the	 clinical	 situation	 evolves,	 while	 not	





preserved	 CD4	 cell	 count.	 Some	 people	 would	 remain	
clinically	 inappropriate	 for	 same-	day	 ART:	 for	 exam-
ple,	 those	 who	 are	 not	 psychologically	 ready	 for	 ART,	
or	who	have	signs	and	symptoms	of	central	nervous	sys-
tem	infection.
In	 summary,	 we	 identified	 only	 four	 studies	 that	 de-




mary	 aim.	Two	 studies	 showed	 that	 by	 deferring	 ART	 in	
all	people	with	TB	symptoms,	relatively	large	proportions	





people	 to	 achieve	 retention	 in	 care	 and	 viral	 suppression	
at	12 months.	This	is	an	important	issue	that	affects	large	
numbers	of	people	as	they	start	ART.	The	safety	of	same-	
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